Organization | Malaria Vaccine and Drug Development Center

Malaria Vaccine and Drug Development Center Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2005

NCT01081847

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Malaria Vaccine and Drug Development Center

Active Ingredients

Drugs in Phase 2 Trials (5)

is-51 (1 trial)

p. vivax irradiated sporozoites (1 trial)

synthetic cs protein of plasmodium vivax (1 trial)

vaccine pvcs n+c (1 trial)

vaccine pvcs n+c+r (2 trials)

Drugs in Phase 1 Trials (3)

isa-51 (1 trial)

isa-720 (1 trial)

peptides (n, r & c) from p. vivax cs protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Malaria (Phase 2)

Malaria, Vivax (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 8